NF-κB and cancer: Mechanisms and targets
✍ Scribed by Michael Karin
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 120 KB
- Volume
- 45
- Category
- Article
- ISSN
- 0899-1987
- DOI
- 10.1002/mc.20217
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In addition to being a central coordinator of immune responses, NF‐κB signaling also plays a critical role in cancer development and progression and it may determine the response to therapy. NF‐κB activation was shown to provide a critical mechanistic link between inflammation and cancer and is a major factor that controls the ability of both preneoplastic and malignant cells to resist apoptosis‐based tumor surveillance mechanisms. NF‐κB may also be involved in regulation of tumor angiogenesis and invasiveness. Importantly, NF‐κB and the signaling pathways that mediate its activation have become attractive targets for development of new chemopreventive and chemotherapeutic approaches. © 2006 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
A new NF-kappaB inhibitor, dehydroxymethylepoxyquinomicin (DHMEQ), inhibited proliferation and induced apoptosis in human Burkitt lymphoma, HS-Sultan and Daudi cell lines. The activation of caspase-3 and the cleavage of caspase substrate PARP were observed after treatment with DHMEQ. The induction o
## Abstract During progression of an in situ to an invasive cancer, epithelial cells lose expression of proteins that promote cell–cell contact, and acquire mesenchymal markers, which promote cell migration and invasion. These events bear extensive similarities to the process of epithelial to mesen